Letters Section Editor: Robert M. Golub, MD, Senior Editor.
To the Editor: In his Clinical Crossroads article, Dr Come1 outlines adjuvant therapy options for postmenopausal breast cancer patients and raises safety concerns for aromatase inhibitors regarding fractures and lipid profile change. However, no protocol-defined screening or therapy related to bone health was used in any aromatase inhibitor trial, and guidelines are now available to inform management of this issue.2
Chlebowski RT. Aromatase Inhibitors and Breast Cancer Treatment. JAMA. 2006;296(6):651. doi:10.1001/jama.296.6.651-a